Efficacy of azithromycin 1% and 1.5% ophthalmic solutions compared to tobramycin 0.3% eye drops: A systematic review and meta-analysis

被引:2
|
作者
Alemu, Birhanu Motbaynor [1 ]
Worku, Teshager [2 ]
机构
[1] Haramaya Univ, Coll Hlth & Med Sci, Sch Pharm, POB 235, Harar, Ethiopia
[2] Haramaya Univ, Coll Hlth & Med Sci, Sch Nursing & Midwifery, Harar, Ethiopia
来源
SAGE OPEN MEDICINE | 2020年 / 8卷
关键词
Azithromycin; eye diseases; eye drops; tobramycin; efficacy; PURULENT BACTERIAL CONJUNCTIVITIS; CLINICAL-EFFICACY; 3-DAY TREATMENT; EYEDROPS; SAFETY; SIGNS; MULTICENTER; SYMPTOMS; TRIAL;
D O I
10.1177/2050312120958846
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Azithromycin 1% and 1.5% ophthalmic preparations are used widely in clinical practice for the treatment of signs and symptoms of eye diseases. The aim of this study was to render conclusive evidence by comparing the efficacy of azithromycin 1% and 1.5% over tobramycin 0.3% ophthalmic solutions for the treatment of eye diseases in a short duration in terms of bacterial resolution, the cure rate, and resolving clinical sign and symptoms. Methods: Systematic searches were performed in the electronic database (MEDLINE, Embase, Emcare, CINAHL, Scopus, PubMed, ProQuest, and Web of Science) and other sources. Multicenter randomized controlled trial studies conducted in English were identified and screened. Analysis of individual studies was conducted using the OpenMeta-analyst and Review Manager Version 5.3 software. Results: Eleven studies were included in the systematic review and meta-analysis. In clinical cure rate, azithromycin 1% and 1.5% eye drops were more effective than tobramycin 0.3% eye drops in short duration dosing (<= 5 days) with a twice-a-day regimen (relative risk = 1.13; 95% confidence interval: 1.008, 1.28), whereas on increased duration (>5 days), azithromycin is almost similarly as effective as tobramycin (relative risk = 1.007; 95% confidence interval: 0.96, 1.05). There was no significant difference in efficacy of bacterial resolution of azithromycin (1%, 1.5%) eye drops compared to tobramycin (0.3%) eye drops (relative risk = 0.99; 95% confidence interval: 0.96, 1.018). Azithromycin eye drops are effective in improving the signs and symptoms of eye disease. Conclusion: Azithromycin 1% or 1.5% is more effective in the clinical cure rate of eye disease than tobramycin 0.3% eye drops in <= 5 days of treatment. It is also the best choice of treatment for improving the signs and symptoms of eye disease. So that we recommend clinicians to use azithromycin 1% or 1.5% eye drops.
引用
收藏
页数:11
相关论文
共 50 条
  • [11] Atropine 0.01% eye drops slow myopia progression: a systematic review and Meta-analysis
    Zhao, Ying
    Feng, Kai
    Liu, Rui-Bao
    Pan, Jin-Hua
    Zhang, Lai-Lin
    Xu, Zhu-Ping
    Lu, Xue-Jing
    INTERNATIONAL JOURNAL OF OPHTHALMOLOGY, 2019, 12 (08) : 1337 - 1343
  • [12] Atropine 0.01% eye drops slow myopia progression: a systematic review and Meta-analysis
    Ying Zhao
    Kai Feng
    Rui-Bao Liu
    Jin-Hua Pan
    Lai-Lin Zhang
    Zhu-Ping Xu
    Xue-Jing Lu
    International Journal of Ophthalmology, 2019, 12 (08) : 1337 - 1343
  • [13] Serum eye drops for the treatment of ocular surface diseases: a systematic review and meta-analysis
    Franchini, Massimo
    Cruciani, Mario
    Mengoli, Carlo
    Marano, Giuseppe
    Capuzzo, Enrico
    Pati, Ilaria
    Masiello, Francesca
    Veropalumbo, Eva
    Pupella, Simonetta
    Vaglio, Stefania
    Liumbruno, Giancarlo M.
    BLOOD TRANSFUSION, 2019, 17 (03) : 200 - 209
  • [14] Different concentrations of hyaluronic acid eye drops for dry eye syndrome: a systematic review and Meta-analysis
    Ouyang, Xiao-Wei
    Fang, Sheng
    Yi, Yun-Min
    Zou, Shi-Peng
    Hu, Qi-Yu
    Huang, Zi-Xuan
    Li, Qing-Xia
    Luo, Jin-Yan
    INTERNATIONAL JOURNAL OF OPHTHALMOLOGY, 2024, 17 (06) : 1110 - 1119
  • [15] Safety of azithromycin in pediatrics: a systematic review and meta-analysis
    Linan Zeng
    Peipei Xu
    Imti Choonara
    Zhenyan Bo
    Xiangchen Pan
    Wenyan Li
    Xiaofeng Ni
    Tao Xiong
    Can Chen
    Leshan Huang
    Shamim Ahmad Qazi
    Dezhi Mu
    Lingli Zhang
    European Journal of Clinical Pharmacology, 2020, 76 : 1709 - 1721
  • [16] Safety of azithromycin in pediatrics: a systematic review and meta-analysis
    Zeng, Linan
    Xu, Peipei
    Choonara, Imti
    Bo, Zhenyan
    Pan, Xiangchen
    Li, Wenyan
    Ni, Xiaofeng
    Xiong, Tao
    Chen, Can
    Huang, Leshan
    Qazi, Shamim Ahmad
    Mu, Dezhi
    Zhang, Lingli
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 76 (12) : 1709 - 1721
  • [17] Efficacy and Safety of Azithromycin for the Treatment of COVID-19: A Systematic Review and Meta-analysis
    Mangkuliguna, B. M. Ghea
    Glenardi, B. M.
    Natalia, B. M.
    Pramono, Laurentius A.
    TUBERCULOSIS AND RESPIRATORY DISEASES, 2021, 84 (04) : 299 - 316
  • [18] The efficacy of azithromycin and doxycycline for the treatment of rectal chlamydia infection: a systematic review and meta-analysis
    Kong, Fabian Yuh Shiong
    Tabrizi, Sepehr N.
    Fairley, Christopher Kincaid
    Vodstrcil, Lenka A.
    Huston, Wilhelmina M.
    Chen, Marcus
    Bradshaw, Catriona
    Hocking, Jane S.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2015, 70 (05) : 1290 - 1297
  • [19] Efficacy of doxycycline versus azithromycin for the treatment of rectal chlamydia: a systematic review and meta-analysis
    Chen, Liang-Fu
    Wang, Ting-Cheng
    Chen, Fu-Lun
    Hsu, Shih-Chang
    Hsu, Chin-Wang
    Bai, Chyi-Huey
    Hsu, Yuan-Pin
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2021, 76 (12) : 3103 - 3110
  • [20] Efficacy of adding azithromycin to antibiotic prophylaxis in caesarean delivery: a meta-analysis and systematic review
    Yang, Mengqi
    Yuan, Fang
    Guo, Yujin
    Wang, Shan
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2022, 59 (03)